Beware of suboptimal medical management of patients with atherosclerosis requiring revascularization

International Angiology

Volumn 31, Issue 3, 2012, Pages 260-270

  Le Hello, C ^a   Morello, R ^a   Fradin, S ^a   Coffin, O ^a   Maiza D ^a   Hamon, M ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Atherosclerosis; Cohort follow up; Medical management

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TICLOPIDINE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; DIABETES MELLITUS; ENDOVASCULAR SURGERY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; OBESITY; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROGNOSIS; PROSPECTIVE STUDY; REVASCULARIZATION; SMOKING; SUPRAAORTIC VESSEL DISEASE; VISCERAL ARTERY DISEASE;

AGED; ATHEROSCLEROSIS; ENDOVASCULAR PROCEDURES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84864761909     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison or EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-40.
2. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Reiner Z et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010;17:530-40.
3. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-9.
4. Dagenais GR, Yi Q, Lonn E, Sleight P, Ostergren J, Yusuf S et al. Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial. Eur J Cardiovasc Prev Rehabil 2005;12:75-81.
5. Dagenais GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005;149:54-60.
6. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67.
7. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59.
8. Feringa HH, Karagiannis SE, Vidakovic R, Elhendy A, Schouten O, Boersma E et al. Glycemic control, lipid-lowering treatment, and prognosis in diabetic patients with peripheral atherosclerotic disease. Ann Vasc Surg 2007;21:780-9.
9. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
10. Control Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-98.
11. Mehta RH, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS et al. Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry. Eur Heart J 2008;29:3052-60.
12. Cacoub PP, Abola MT, Baumgartner I, Bhatt DL, Creager MA, Liau CS et al. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis 2009;204:e86-92.
13. Van Ganse E, Souchet T, Laforest L, Moulin P, Bertrand M, Le Jeunne P et al. Ineffectiveness of lipid-lowering therapy in primary care. Br J Clin Pharmacol 2005;59:456-63.
14. Gitt AK, Jünger C, Šmolka W, Bestehorn K. Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. Clin Res Cardiol 2010;99:723-33.
15. Vulic D, Lee BT, Dede J, Lopez VA, Wong ND. Extent of control of cardiovascular risk factors and adherence to recommended therapies in US multiethnic adults with coronary heart disease: from a 2005-2006 national survey. Am J Cardiovasc Drugs 2010;10:109-14.
16. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17-24.
17. Blacher J, Cacoub P, Luizy F, Mourad JJ, Levesque H, Benelbaz J et al. Peripheral arterial disease versus other localizations of vascular disease: the ATTEST study. J Vasc Surg 2006;44:314-8.
18. Khan S, Flather M, Mister R, Delahunty. N, Fowkes G, Bradbury A et al. Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: results of a prospective registry. Eur J Vasc Endovasc Surg 2007;33:442-50.
19. Cambou JP, Aboyans V, Constans J, Lacroix P, Dentans C, Bura A. Characteristics and outcome of patients hospitalised for lower extremity peripheral artery disease in France: the COPART Registry. Eur J Vasc Endovasc Surg 2010;39:577-85.
20. Feringa HH, Vidakovic R, Karagiannis SE, Dunkelgrun M, Elhendy A, Boersma E et al. Impaired glucose regulation, elevated glycated haemoglobin and cardiac ischaemic events in vascular surgery patients. Diabet Med 2008;25:314-9.
21. Halkos ME, Lattouf OM, Puskas JD, Kilgo P, Cooper WA, Morris CD et al. Elevated preoperative hemoglobin A1c level is associated with reduced long-term survival after coronary artery bypass surgery. Ann Thorac Surg 2008;86:1431-7.
22. Feringa HH, Bax JJ, Karagiannis SE, Noordzij P, van Domburg R, Klein J et al. Elderly patients undergoing major vascular surgery: risk factors and medication associated with risk reduction. Arch Gerontol Geriatr 2009;48:116-20.
23. Schouten O, Hoeks SE, Welten GM, Davignon J, Kastelein JJ, Vidakovic R et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007;100:316-20.
24. Bongard V, Cambou JP, Lezorovcz A, Ferrères J, Vahanan A, Julien G et al. Comparison of cardiovascular risk factors and drug use in 14,544 French patients with a history of myocardial infarction, ischaemic stroke and/or peripheral arterial disease. Eur J Cardiovasc Prev Rehabil 2004;11:394-402.
25. Steinberg BA, Steg PG, Bhatt DL, Fonarow GC, Zeymer U, Cannon CP. Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry). Am J Cardiol 2007;99:1212-5.
26. Touzé E, Mas JL, Röther J, Goto S, Hirsch AT, Ikeda Y et al. Impact of carotid endarterectomy on medical secondary prevention after a stroke or a transient ischemic attack: results from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Stroke 2006;37:2880-5.
27. Alberts MJ, Bhatt DL, Mas JL, Ohman EM, Hirsch AT, Röther J et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J 2009;30:2318-26.
28. Norgren L, Hiatt WR, Dormandy JA, Hirsch AT, Jaff MR, Diehm C et al. The next 10 years in the management of peripheral artery disease: perspectives from the 'PAD 2009' Conference. Eur J Vasc Endovasc Surg 2010;40:375-80.
29. Hirsch AT, Murphy TP, Lovell MB, Twillman G, Treat-Jacobson D, Harwood EM et al. Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey. Circulation 2007;116:2086-94.
30. Davenport DL, Xenos ES, Hosokawa P, Radford J, Henderson WG, Endean ED. The influence of body mass index obesity status on vascular surgery 30-day morbidity and mortality. J Vasc Surg 2009;49:140-147.
31. Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthélémy O et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2Cl9*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010;56:134-43.
32. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.